Dilafor is in the process of identifying strategic partners interested in developing and commercializing tafoxiparin globally or regionally.

Please contact:
Lena Degling Wikingsson, CEO

Up to 50 % of all term pregnant women are planned for start of labor with conventional treatments, which carries a high risk of complications for both mothers and infants.